complexes (4a–g) have been prepared. The cytotoxic activity of the new ruthenium(II) and iridium(III) compounds has been evaluated in a panel of cell lines (A2780, A2780cisR, A427, 5637, LCLC, SISO, and HT29) in order to investigate structure–activity relationships. Phenyl substitution at the R4 position shows increased potency in both Ru and Ir complexes (3g and 4g, respectively) as compared to their parent
一系列新颖的C,N-环
金属化的
苯并咪唑钌(II)和
铱(III)的类型的配合物[(η 6 - p -cymene)的RuCl(κ 2 - Ñ,Ç -L)]和[(η 5 - ç 5我5)的IrCl(κ 2 - ñ,ç -L)](HL =甲基1-丁基-2- arylbenzimidazolecarboxylate)具有不同的取代基(H中,Me,F,CF 3,的MeO,NO 2,和pH下)在R 4的
钌的2-苯基苯并螯合
配体(的苯基环的位置3a中-克)和
铱配合物(4A– g)已经准备好。为了研究结构-活性之间的关系,已经在一组
细胞系(A2780,A2780cisR,A427、5637,LCLC,SISO和HT29)中评估了新的
钌(II)和
铱(III)化合物的细胞毒活性。在所有
细胞系中,与它们的母体化合物(3a和4a)相比,R 4位置的苯基取代在Ru和Ir配合物(分别为3g和4g)中均显示出增强的效力